Dr. David Louis is Benjamin Castleman Professor of Pathology and chair of Mass General Pathology. His clinical practice and research focuses on the molecular basis of brain tumors and the application of molecular diagnostics to their classification.
- Centers & Specialties
- Neuro-Oncology (Brain)
- Clinical Interests
- Autopsy Pathology
- Frozen Section Pathology
- Medical Education
- MD, SUNY at Stony Brook School of Medicine
- Residency, Albany Medical Center|Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
- Board Certifications
- Anatomic Pathology
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Maine
- OSW - New Hampshire
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
David N. Louis, MD, is the Benjamin Castleman Professor of Pathology at Harvard and chair of Pathology at Mass General Hospital. Dr. Louis' clinical practice and research has focused on the molecular basis of brain tumors and the application of molecular diagnostics to brain tumor classification. He has published more than 250 original articles, as well as numerous reviews, chapters and books. His laboratory was the first to demonstrate that molecular approaches could be used to subdivide malignant gliomas in a biologically relevant manner, and that molecular approaches could be used to predict the response of particular malignant gliomas to specific therapies, work that has led to worldwide adoption of molecular testing for the management of brain tumor patients. As a result, Dr. Louis co-chaired and was the primary editor for the 2007 WHO brain tumor classification and is currently guiding the WHO brain tumor revision expected in 2016. He has received prestigious awards for this work, has served on multiple advisory and editorial boards, and has authored and/or edited many of the major textbooks in neuropathology. He was co-chair of the Brain Tumor Progress Review Group sponsored by the NIH, and was the founding chair of the Cancer Biomarkers Study Section at the NIH. Under Dr. Louis’ chairmanship, Mass General Pathology has become a national leader in molecular diagnostics and pathology informatics, leading to the development of the novel discipline of computational pathology.
- Research Summary
Malignant gliomas of the cerebral hemispheres in adults are the most common brain tumors. They are the focus of the David N. Louis Laboratory efforts. Malignant gliomas are classified as astrocytomas, oligodendrogliomas, and oligoastrocytomas. The most aggressive, astrocytoma, is referred to as glioblastoma. Elucidating the molecular basis of glioma formation may impact both diagnostic and therapeutic aspects of clinical neuro-oncology.
Visit the David N. Louis Research Laboratory to learn more.
2005 - Histology-Based Expression Profiling Yields Novel Prognostic Markers in Human Glioblastoma - JNEN (PDF)
Supplementary Information Table 1.xls
Supplementary Information Table 2.xls
Supplementary Information Table 3.xls
The 69th meeting of the MGH Scientific Advisory Committee (SAC), on April 6 and 7, focused on the hospital&rsquo;s five thematic research centers.
Medical laboratory professionals week &ndash; an annual celebration of laboratory professionals and pathologists who play a vital role in every aspect of health care &ndash; runs from April 24-30.
Many &lsquo;keen minds&rsquo; have worked toward a better understanding of disease to enable improved diagnosis and treatment.
55 Fruit Street
Boston, MA 02114-2696